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SUMMARY Treatment of cutaneous leishmaniasis is often difficult. Even though 
most cutaneous lesions will heal spontaneously, their duration cannot be predicted 
in an individual case. In general, only large, multiple or diffuse lesions of the face, 
head and neck need to be considered for therapeutic intervention. Pentavalent 
antimonials (sodium stibogluconate and meglumine antimoniate) administered 
intralesionally or parenterally (IM or IV) are the mainstays of systemic therapy 
despite the toxicity associated with their use. The objective of this study was to 
compare the clinical efficacy of intramuscular pentavalent antimonial compound 
meglumine antimoniate alone and in combination with intralesional therapy in 
the treatment of Old World cutaneous leishmaniasis. Study was conducted as a 
case controlled interventional prospective study. On the basis of demonstration of 
Leishmania tropica (LT) bodies in the skin slit smears/skin biopsies, 60 patients with 
cutaneous leishmaniasis were included in the study. The patients were randomly 
allocated to three groups of 20 patients each: group 1 treated with intramuscular 
injection of meglumine antimoniate (20 mg Sb/kg/day, maximum 850 mg) for 21 
days; group 2 treated with intralesional injection of meglumine antimoniate (0.5 mL, 
42.5 mg of Sb) into each lesion along with intramuscular injection of meglumine 
antimoniate (20 mg Sb/kg/day, maximum 850 mg) for 21 days; and group 3 as a 
control group. The patients were followed-up for therapeutic safety and efficacy at 
10, 20 and 90 days. The rate of complete cure was 55% in group 1, 75% in group 
2 and 10% of spontaneous cure cases in group 3. The conclusions derived from 
this study are limited by the relatively small number of patients. The combination of 
intramuscular meglumine antimoniate along with intralesional administration of the 
agent is superior therapy to intralesional administration of meglumine antimoniate 
alone. 
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IntRODUCtIOn
Leishmaniases represent a spectrum of sev-
eral vector-borne parasitic diseases of variable 
severity, ranging from self-healing cutaneous pap-
ular or ulcerated lesions to life-threatening visceral 
disease, each caused by one of the species of the 
genus Leishmania. Leishmaniasis is endemic in 
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88 countries throughout Asia, Africa, Europe and 
North and South America, and the population at 
risk is more than 350 million (1).
The parasite is transmitted to humans by the 
bites of infected female sandflies (Phlebotomus in 
the Old World countries and Lutzomyia in the New 
World). Leishmaniases are classified into three 
forms: cutaneous (oriental sore), mucocutaneous 
(espundia) and visceral (kala azar).
The World Health Organization estimates that 
at least 1.5 million cases of cutaneous leishmani-
asis and 500,000 cases of visceral leishmaniasis 
occur each year (1). Individuals at high risk of 
cutaneous leishmaniasis include military person-
nel and those who travel to or live in areas of the 
tropics, subtropics and southern Europe where 
the disease is endemic (1,2). Approximately 90% 
of all cases of cutaneous leishmaniasis occur in 
Afghanistan, Brazil, Iran, Peru, Saudi Arabia and 
Syria. Cutaneous leishmaniasis is endemic along 
the northern areas of Baluchistan, Sindh, tribal 
area (refugees from Afghanistan), and western 
border of Pakistan. Sporadic cases have been 
reported from southern Punjab, Azad Kashmir, 
northern areas and Islamabad (3,4).
The pentavalent antimony compounds sodium 
stibogluconate and meglumine antimoniate have 
been the mainstays of antileishmanial therapy for 
both visceral and cutaneous leishmaniasis (5,6).
Rifampicin, ketoconazole, allopurinol, itracon-
azole, liposomal amphotericin B, topical paromomy-
cin and dapsone were used in various studies, how-
ever, with conflicting results (7-11). The aim of the 
study was to monitor and compare clinical response 
to intramuscular meglumine antimoniate (MA) alone 
and in combination with intralesional meglumine an-
timoniate in cutaneous leishmaniasis.  
PAtIEntS AnD MEthODS
This case controlled interventional prospective 
study evaluated 60 patients admitted to Depart-
ment of Medicine, Scouts Hospital Wana from 
January 2003 to December 2004. There were no 
sex differences. All patients were adults, their age 
ranging from 14 to 55 years and the number of le-
sions 2-5 per patient (Figures 1-10). The inclusion 
criteria were demonstration of Leishmania tropica 
(LT) bodies in skin slit smears/skin biopsies and 
Figure 1. Excoriated crusted plaques with ery-
thematous indurated borders on the lower back.
Figure 2. Close-up view of Figure 1.
Figure 3. Erythematous indurated plaque on the 
back of left elbow.
lesions of less than 8-week duration to standard-
ize the trial. The patients who had lesions more 
than 8 weeks old, those who had already been 
treated, patients with known hypersensitivity to 
antimonial compounds, those with cardiovascular, 
renal, hepatic or hematologic disorders and preg-
nant women were excluded from the study.
Selected patients were explained the study 
purpose and gave their consent for inclusion. They 
were randomly divided into three groups of 20 pa-
tients each: group 1 received 20 mg of Sb/kg/day 
by intramuscular injection daily for 21 days; group 
2 received 20 mg of Sb/kg/day by intramuscular 
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injection along with 0.5 mL (42.5 mg of meglumine 
antimoniate) into each lesion, upper and mid-der-
mis daily; and group 3 consisting of patients unwill-
ing to receive treatment, thus serving as a control 
group. The patients were evaluated at 10, 20 and 
90 days. The absence of exudation, erythema, in-
duration and LT bodies in skin slit smears/biopsies 
was considered as a parameter of cure. Adverse 
effects were also recorded during treatment. Re-
sults were analyzed using x2 method to calculate 
percentage, and p value was obtained according 
to appropriate degree of freedom.   
RESUltS
Data on 60 study patients, mean age 27 years 
and a mean of 3 lesions, are shown in Table 1. 
Complete cure was ascertained by clinical and 
laboratory parameters already discussed. The pa-
tients on combination therapy with intramuscular 
and intralesional meglumine antimoniate showed 
better response (Table 2). At the end of follow up, 
complete cure was achieved in 11 of 20 (55%) pa-
tients in group 1 (p-0.001), 15 of 20 (75%) patients 
in group 2 (p-0.00001) and only two of 20 (10%) 
patients in group 3 as a control group.
table 2. Response to intramuscular meglumine antimoniate alone and in combination with intralesional 
therapy
10 days 20 days 90 days
Group 1 7/20 (35%) 10/20 (50%) 11/20 (55%)
Group 2 9/20 (45%) 10/20 (50%) 15/20 (75%)
Group 3 1/20 (5%) 3/20(15%) 2/20 (10%)
table 1. Clinical data   
No. of patients Mean age (yrs) Duration (weeks) Number of lesions
Group 1 20 25 (12-45) 6 (1-8) 4 (2-6)
Group 2 20 26 (18-50) 5 (1-8) 2 (2-6)
Group 3 20 30 (20-55) 5 (1-8) 3 (2-6)
Figure 4. Close-up view of Figure 3.
Adverse effects recorded in study patients are 
presented in Table 3. Myalgia, arthralgia, head-
ache, nausea, urticaria and cardiomyopathy were 
common in group 2 (combination therapy), while 
cellulitis and pain at the injection site were com-
mon in group 1. Cardiomyopathy was observed 
in only one group 2 patient, with tachycardia and 
nonspecific ECG changes at 3 weeks of treatment, 
however, these changes reverted to normal upon 
therapy discontinuation.
Figure 5. A crusted ulcer with indurated borders 
on the left forearm, and an indurated erythema-
tous plaque on the left arm.
DISCUSSIOn
The treatment of cutaneous leishmaniasis is still 
controversial despite the fact that a wide variety of 
oral, parenteral, topical, surgical, combination and 
cryotherapy had been tried in the past with con-
flicting results in various studies. Pentavalent an-
timonial compounds, sodium stibogluconate and 
meglumine antimoniate, are still the drugs of first 
choice. The two compounds have almost similar 
efficacy and toxicity. Parenteral administration of 
meglumine antimoniate showed variable efficacy 
from 65% to 95% in various studies (12-16). 
In our study, group 1 administered only in-
tramuscular therapy showed 55% cure rate that 
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increased to 75% when intramuscular treatment 
was added to intralesional therapy which was in 
conformity to previous studies (12). A minor dif-
ference may have been due to different or resis-
tant parasite strain or technique of intralesional 
treatment; however, in group 2 the efficacy was 
enhanced and the cost of few adverse effects 
(Table 3) as compared with group 1. Therapeutic 
therapy, whereas for multiple and extensive le-
sions intramuscular therapy combined with intra-
lesional therapy will be more effective than either 
therapy alone.
In group 3, three (15%) patients showed spon-
taneous healing, one of them developing relapse 
at six months; the overall cure of 10% indicates 
that most patients require therapy, especially if the 
lesions are multiple, extensive, disfiguring, dis-
seminating, and located at cosmetically unaccept-
able sites and joints.  
table 3. Adverse effects of treatment   
Adverse effect Group 1 Group 2 Group 3
Arthralgia 1 (5%) 3 (15%) -
Myalgia 1 (5%) 3 (15%) -
Headache - 2 (10%) -
Urticaria - 1 (5%) -
Cardiomyopathy - 1 (5%) -
Cellulitis 2 (10%) 1 (5%) -
Pain at injection site 4 (20%) 1 (5%) -
Renal toxicity - - -
Hepatic toxicity - - -
Drug fever - - -
Figure 6. Close-up view of Figure 5.
Figure 7. An erythematous indurated plaque with 
crusted ulcer.
decision depends on the site of lesion, e.g., face, 
which is too sensitive to be treated by intralesional 
route. Single lesions, especially on the extremi-
ties, may be treated exclusively by intralesional 
Figure 8. Close-up view of Figure 7.
Figure 9.  An ulcerated lesion with indurated bor-
ders on the left foot and a similar lesion on the 
right lower leg.
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Adverse effects commonly reported were my-
lagias, arthralgias, headache, urticaria, cellulitis 
and pain at injection sites. These were transient 
and disappeared upon treatment discontinuation, 
however, regular follow up for cardiac, hepatic, re-
nal and hematologic toxicity was performed; only 
one patient developed early cardiotoxicity at the 
end of the 3rd week of treatment that normalized 
upon treatment discontinuation. 
COnClUSIOn
Treatment of cutaneous leishmaniasis with 
combination therapy consisting of intramuscular 
and intralesional meglumine antimoniate showed 
high efficacy at the cost of few side effects. How-
ever, intralesional therapy should only be admin-
istered in case of multiple, extensive and dissemi-
nating lesions. 
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